share_log

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A:證券上市註冊聲明(修正)
美股SEC公告 ·  09/28 05:05

牛牛AI助理已提取核心訊息

Heart Test Laboratories, Inc. (HeartSciences), a medical technology company, has announced a securities offering of up to 1,882,353 shares of its common stock. The offering is being managed by Maxim Group LLC as the exclusive placement agent. The company has also agreed to issue placement agent warrants for the purchase of up to 75,294 shares of common stock, with the warrants exercisable at 110% of the public offering price. The offering is being conducted on a best-efforts basis, with no minimum amount of securities required to be sold for the offering to proceed. The actual public offering price will be determined through negotiations between HeartSciences, the placement agent, and investors. The offering is subject to various terms and conditions as outlined in...Show More
Heart Test Laboratories, Inc. (HeartSciences), a medical technology company, has announced a securities offering of up to 1,882,353 shares of its common stock. The offering is being managed by Maxim Group LLC as the exclusive placement agent. The company has also agreed to issue placement agent warrants for the purchase of up to 75,294 shares of common stock, with the warrants exercisable at 110% of the public offering price. The offering is being conducted on a best-efforts basis, with no minimum amount of securities required to be sold for the offering to proceed. The actual public offering price will be determined through negotiations between HeartSciences, the placement agent, and investors. The offering is subject to various terms and conditions as outlined in a placement agency agreement and securities purchase agreements with investors. HeartSciences intends to use the net proceeds from the offering for FDA clearance-related costs, commercial development of licensed AI cardiovascular algorithms, research and development, working capital, and other general corporate purposes. The offering includes certain lock-up agreements restricting the issuance and sale of additional securities by the company and its officers and directors for specified periods post-offering. The common stock is listed on the Nasdaq Capital Market under the symbol 'HSCS'.
醫療科技公司Heart Test Laboratories, Inc. (HeartSciences)宣佈要發行高達1,882,353股普通股的證券。這次發行由Maxim Group LLC作爲獨家配售代理管理。該公司還同意發行配售代理授出的warrants,用於購買高達75,294股普通股,warrants的行使價格爲公開發行價格的110%。這次發行是根據盡最大努力的原則進行的,沒有規定必須出售的最低證券數量才能進行發行。實際的公開發行價格將通過HeartSciences、配售代理和投資者之間的洽談確定。該發行受放置代理協議和與投資者簽訂的證券購買協議中概述的各種條款和條件約束。HeartS...展開全部
醫療科技公司Heart Test Laboratories, Inc. (HeartSciences)宣佈要發行高達1,882,353股普通股的證券。這次發行由Maxim Group LLC作爲獨家配售代理管理。該公司還同意發行配售代理授出的warrants,用於購買高達75,294股普通股,warrants的行使價格爲公開發行價格的110%。這次發行是根據盡最大努力的原則進行的,沒有規定必須出售的最低證券數量才能進行發行。實際的公開發行價格將通過HeartSciences、配售代理和投資者之間的洽談確定。該發行受放置代理協議和與投資者簽訂的證券購買協議中概述的各種條款和條件約束。HeartSciences打算使用本次發行的淨收益用於FDA清關相關費用,授權的人工智能心血管算法的商業開發,研發,運營資金和其他一般公司用途。該發行包括某些鎖定協議,限制公司及其高管和董事在發行後指定期間內發行和出售額外證券。該普通股已在納斯達克資本市場上以標的『HSCS』上市。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。